Acadia Can't Slip Investor Suit Over Parkinson's Drug Deaths
Acadia Pharmaceuticals escaped part of the securities fraud claims lodged in a proposed class action over its alleged cover-up of fatality risks associated with its Parkinson's disease treatment, but it must...To view the full article, register now.
Already a subscriber? Click here to view full article